Guilford, Conn. – February 19, 2024 -- InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
February 19, 2024
Guilford, Conn. – April 4, 2023 -- InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
April 4, 2023
GUILFORD, Conn. and TOKYO, May 31, 2022 -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery and development
May 31, 2022
GUILFORD, Conn. USA, February 24, 2022, InveniAI® LLC, a global leader in applying Artificial Intelligence
February 24, 2022
GUILFORD, Conn. USA, and TOKYO, Japan, December 16, 2021, InveniAI® LLC, a global leader in applying Artificial
December 16, 2021
Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD
July 20, 2021
Tokyo, Japan, and Cambridge, UK, 6 July 2021 – Sosei Group Corporation (“the Company”; TSE: 4565),
July 06, 2021
GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global
May 11, 2021
Teams will work together by leveraging InveniAI's technology
April 27, 2021
Expansion of existing collaboration will leverage InveniAI
December 09, 2020
Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial
September 09, 2020
Three-year strategic collaboration to leverage InveniAI’s AI
July 29, 2020
TB Alliance to leverage AlphaMeld®, an AI-powered platform
June 02, 2020
TargetMeld™ and RxMeld™ to provide predictive analytics and comprehensive access to emerging targets
November 06, 2019
InveniAI Launches Suite of Products Powered by AlphaMeld®
September 17, 2019
Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology
July 02, 2019
Focus on identifying therapies in hard to treat diseases to serve unmet patient needs
May 29, 2019
GUILFORD, CT., March 26, 2019 — InveniAI® Corporation, a global leader pioneering the application
March 06, 2019
GUILFORD, Conn., Mar. 01, 2019 — InveniAI® Corporation, a global leader in pioneering the application of artificial
March 01, 2019
Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial
December 11, 2018
InveniAI’s CSO discussing diversity and disparity and increasing diagnosis rates for celiac disease in the US in a town hall meeting at
July 11, 2021
InveniAI’s CBO, Aman Kant, featured in BioCT’s The Stories Behind the Science series where he shares his academic and professional journey to date.
July 10, 2021
Creating transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform,
July 06, 2021
Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure
July 06, 2021
A new R&D collaboration between Japanese drugmaker Sosei Group and USA-based InveniAI will see the firms
July 06, 2021
Krishnan Nandabalan, Ph.D., President and CEO, InveniAI, LLC., Keynote Speaker at TEDxUNewHaven, “Looking at Tomorrow from Today,” April 17, 2021
April 17, 2021
Guilford-based company InveniAI LLC, which uses artificial intelligence for drug discovery and
May 14, 2021
InveniAI and Kyowa Kirin recently reported an expansion of a collaboration agreement, using InveniAI’s
January 27, 2021
Dr. Krishnan Nandabalan talks to Tilde Cafe attendees about the benefits of using AI to identify
May 26, 2020
After a bumpy start to testing for COVID-19, the global healthcare community has banded together
April 13, 2020
Introduction: An outbreak of respiratory illness (COVID-19 Disease) caused by a novel coronavirus,
March 26, 2020
As countries scramble to address the coronavirus outbreak that started in Wuhan, China, the U.S. FDA issued
March 04, 2020
Artificial intelligence (AI) far too often pops up as a term used vaguely to refer to any process that appears
January 29, 2020
AI’s Role In Redefining Consumer Health & Drug evelopment-Featured Guest Krishnan Nandabalan
November 05, 2019
InveniAI Corporation CEO Krishnan Nandabalan sat down with Proactive at the 2019 BIO Investor Forum in San Francisco.
October 28, 2019
Among the many examples of Artificial Intelligence, AI in healthcare is clearly one of the leaders.
October 09, 2019
Thank you Moira Gunn for a wonderful conversation with our President and CEO,
September 29, 2019
This interview is part of our new AI in Healthcare series, where we interview the world’s top
August 30, 2019
Some biopharmaceutical enterprises are taking a leap of faith by reviving failed
August 12, 2019
Daniel Levine, principal of the Levine Media Group, and host of Bio Report and RARECast podcasts
June 04, 2019
Wading through oceans of information can be difficult if not impossible for
May 30, 2019
To date, the healthcare industry has had limited success in developing treatments for rare diseases.
May 30, 2019
Invited to attend Exclusive Bloomberg Digital Disruption Think Tank Meet
May 21, 2019
Artificial intelligence and machine learning platform to drive innovation for rare disease
February 29, 2019
BRANFORD, CT December 11, 2018, InveniAI® Corporation, a global leader in pioneering the
January 11, 2019
Here are some conferences and events our team will be attending!
Jun 10-11 & 14-18, 2021
Events Here
Copyright 2023 InveniAI LLC.
All Rights Reserved
